Skip to Content

Lonza Group Ltd ADR LZAGY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Lonza Group is a contract development and manufacturing organization. It also produces microbicides and other chemicals for personal care, health and hygiene, agrochemical, and industrial preservation markets. The firm is organized into two segments: Pharma Biotech and Nutrition, which encompasses drug development and manufacturing as well as consumer health manufacturing, and Specialty Ingredients, which encompasses businesses in industrials, consumer care, and agriculture. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic and government research organizations, and consumer goods and industrial companies.

Contact
Muenchensteinerstrasse 38
Basel, 4002, Switzerland
T +41 613168111
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings
Fiscal Year End Dec 31, 2020
Stock Type
Employees 15,913